Randy Alexander, President and CEO
Randy Alexander is a leader in the ophthalmic industry. He has consistently created value, delivered growth and implemented new technology, including successfully launching four start-up companies.

He is the President and CEO of ReVision Optics™, Inc. and a seasoned senior executive and leader in the ophthalmic industry. Most recently as CEO of IntraLase Inc., Mr. Alexander grew the business from a start-up to over $18 million in revenue in a little over four years.

During this period, Mr. Alexander was instrumental in raising $75 million in capital for IntraLase. Prior to IntraLase, Mr. Alexander was Senior Vice President of Chiron Vision, where he established Chiron Vision as a leader in the refractive surgery industry. At Chiron Vision, he created a $50 million refractive product line by identifying the LASIK surgical procedure, as well as acquiring patents and instrumentation.

Gilbert H. Kliman, MD
Gilbert H. Kliman, MD, focuses on life sciences investing with a special interest in medical devices. He is responsible for a broad portfolio of InterWest Partner's life sciences companies, including Archus Orthopedics, Epocrates, IntraLase (ILSE), Neuropace and Ophthonix. He was one of the early lead investors in Spinal Dynamics, a spine surgery device company that was acquired in 2002 by Medtronic (MDT) for $270M.

Prior to InterWest Partners, Dr. Kliman was a healthcare investor at TA Associated and at Northwest Venture Capital. As a practicing ophthalmologist he was the former west coast director of LCA Vision, and served as an assistant professor at Tufts New England Eye Center.

Wende Hutton
Seasoned healthcare investor Wende Hutton is passionate about identifying, investing in and building companies that are revolutionizing the practice of medicine. She joined Canaan in 2004, bringing diverse expertise from across the entire medical spectrum. Over the last 15 years, Wende has facilitated the market entrance of over 11 novel and lifesaving medical devices, new drugs and diagnostics. Her track record is a testament to her leadership and includes the initial public offerings of five companies, of which two were later acquired, and the acquisition of four more by medical companies including the recent acquisition of BiPar Sciences, a leader in the development of a potential new class of tumor-selective drugs designed to meet the unmet needs of cancer patients. Wende began her venture career at Mayfield Fund in 1993, where she was a General Partner in the life sciences group until 2001. During her tenure at Mayfield, Wende incubated Heartstream Inc. (HPQ) and Northstar Neuroscience Inc. (NSTR), working closely with those founding teams. Most recently, she was a General Partner at Spring Ridge Ventures, a healthcare-focused seed fund. Earlier in her career, Wende held senior operational management positions at GenPharm International and Nellcor in business development and marketing.

Wende sits on the boards of Altheos, Inc., Calibra Medical, ReVision Optics, Inc., Theraclone Sciences and Transcend Medical, Inc. Her previous board seats include Alsius (ALUS) , Apieron, Inc. (Acquired by Aerocrine), BiPar Sciences (acquired by Sanofi-aventis), Heartstream,
Inc. (acquired by Hewlett Packard), Micro Therapeutics, Inc. (acquired by ev3, Inc.), Northstar Neuroscience (NSTR), Orquest, Inc. (acquired by Johnson & Johnson), and SenoRx, Inc. (NASDAQ: SENO).

Frank M. Fischer
Frank M. Fischer has more than 25 years of senior management experience in the medical device industry. He has served on the NeuroPace Board of Directors since 1998 and joined the company as its Chief Executive Officer in January 2000.

Prior to joining NeuroPace, Mr. Fischer was President and Chief Executive Officer of Heartport, Inc., a cardiac surgery company, from May 1998 until September 1999 and served on Heartport's Board of Directors. Mr. Fischer was President, Chief Executive Officer and a director of Ventritex, Inc., a company that pioneered implantable cardiac defibrillators, from 1987 until the sale of the company to St. Jude Medical, Inc. in early 1997.

Before joining Ventritex, he spent ten years in various management positions at Cordis Corporation in the cardiac and neurosurgical device areas, serving most recently as President of the Implantable Products Division. Prior to that, he spent seven years with General Electric Company in a variety of operating positions.

Mr. Fischer holds an MS in Management from Rensselaer Polytechnic Institute. Currently, he serves on the boards of several privately held medical device companies.

Brian H. Dovey
Brian H. Dovey has been a Partner of Domain Associates since 1988. Since joining Domain, he has served as Chairman of Athena Neurosciences, Creative BioMolecules, and Univax Biologics and on the Board of Directors of over 30 additional companies. Present board memberships include Align Technology, BAS Medical, BioVascular, Neose Technologies, Ocera Therapeutics, Orexigen Therapeutics, Orqis Medical, REVA Medical, SkinMedica, Symphony Medical and Valley Forge Pharmaceuticals. Past board memberships include British Biotech, Cardiac Science, Connetics, Geron, Ista Pharmaceuticals, Nabi, ReSound, Trimeris, U.S. Bioscience, and Vivus. Prior to Domain, Mr. Dovey spent six years at Rorer Group (now Sanofi Aventis as a result of subsequent mergers). As President of Rorer from 1986 to 1988, he was the primary architect of this Fortune 500 company's strategic shift to pharmaceuticals that resulted in a doubling of annual sales to approximately $1 billion.

Previously, Mr. Dovey was President of Survival Technology, a start-up medical products company whose sales growth placed it in the top ten of the Inc 100. He has also held management positions with Howmedica, Howmet Corporation, and New York Telephone. Mr. Dovey has served as both President and Chairman of the National Venture Capital Association. He is Chair of the Wistar Institute and a former member of the Burnham Institute, both of which are leaders in preclinical bio-medical research in the non-profit sector. Mr. Dovey also serves on the Board of Directors of the Kauffman Fellows Program at the Center for Venture Education. He is Trustee Emeritus of Germantown Academy and a former Trustee of the University of Pennsylvania School of Nursing. He is also a former Board Member of the Advanced Medical Technology Association, which represents the medical device industry and the Consumer Healthcare Products Association, which represents the non-prescription pharmaceutical industry.

He received his BA from Colgate University and an MBA from Harvard Business School.

Jay T. Holmes
Jay T. Holmes has been an attorney and business consultant since mid-1996 with extensive ophthalmology industry experience. In addition to serving on the Revision Optics Board of Directors, Mr. Holmes, currently, serves on the board of Occulogix, Inc., a company engaged in the treatment of macular degeneration.

Most recently, Mr. Holmes served on the IntraLase Board from July 2005 until the acquisition of IntraLase by AMO earlier this year. From 1999 to 2005, Mr. Holmes served as a member of the Board of Directors of VISX, Incorporated. From 1981 until mid-1996, Mr. Holmes held several senior management positions at Bausch & Lomb Incorporated, the most recent being Executive Vice President and Chief Administrative Officer from 1995 to 1996 and Senior Vice President and Chief Administrative Officer from 1993 to 1995. Prior to joining Bausch & Lomb, Mr. Holmes was Senior Vice President, Corporate Affairs from 1983 to 1993, and from 1981 to 1983 he was the Vice President and General Counsel at Bausch & Lomb. Mr. Holmes was a member of the Board of Directors of Bausch & Lomb from 1986 until 1996. He earned his BA from the University of Alaska and his JD from the University of Wisconsin.